| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5690424 | Urology | 2017 | 5 Pages |
Abstract
With a median follow-up of 41 months, 18% of this cohort treated with nab-paclitaxel was disease free. Cystectomy-free survival was 61% and bladder cancer-specific mortality was 9%. Nab-paclitaxel is a reasonable treatment option in this high-risk population.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Dennis J. Robins, Wilson Sui, Justin T. Matulay, Rashed Ghandour, Christopher B. Anderson, G. Joel DeCastro, James M. McKiernan,